Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 5.13M | 5.44M | 4.38M | 3.93M | 3.10M |
Gross Profit | 3.67M | 3.50M | 2.40M | 2.50M | 215.51K |
EBITDA | -5.01M | -5.14M | -5.58M | -3.40M | -989.96K |
Net Income | -5.91M | -5.63M | -6.11M | -4.19M | -1.01M |
Balance Sheet | |||||
Total Assets | 9.03M | 8.70M | 13.44M | 18.35M | 20.51M |
Cash, Cash Equivalents and Short-Term Investments | 980.76K | 935.50K | 5.21M | 12.33M | 15.60M |
Total Debt | 961.74K | 128.50K | 284.82K | 14.87K | 46.00K |
Total Liabilities | 2.76M | 1.55M | 1.51M | 1.19M | 387.00K |
Stockholders Equity | 6.27M | 7.15M | 11.92M | 17.16M | 20.13M |
Cash Flow | |||||
Free Cash Flow | -5.38M | -4.98M | -5.75M | -4.04M | -1.17M |
Operating Cash Flow | -4.91M | -4.53M | -5.60M | -3.99M | -864.05K |
Investing Cash Flow | -473.09K | -457.54K | -147.74K | -53.40K | -301.85K |
Financing Cash Flow | 5.43M | 706.43K | -87.33K | 14.92M | 1.79M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $7.50B | 0.31 | -61.87% | 2.27% | 17.10% | 1.59% | |
47 Neutral | AU$8.98M | ― | -375.15% | ― | -59.01% | 17.13% | |
45 Neutral | AU$4.01M | ― | -117.20% | ― | 2.91% | 13.51% | |
41 Neutral | AU$10.76M | ― | -61.15% | ― | 35.63% | 18.55% | |
39 Underperform | AU$9.43M | ― | -98.08% | ― | -7.44% | 30.34% | |
€5.84M | ― | -321.94% | ― | ― | ― | ||
38 Underperform | AU$8.54M | ― | -191.40% | ― | ― | 19.74% |
Control Bionics Limited announced an investor webinar to discuss its quarterly results and recent advancements. The company is enhancing its market position with innovative products like the NeuroNode and DROVE, and is expanding into new sectors with the NeuroStrip®, potentially impacting its operations and stakeholder interests.